Across the past 12 months, open-market trades by Compass Therapeutics insiders were all purchases, totaling $96,850 (62.5K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Thomas J. Schuetz | Chief Executive Officer | 6,603,336 | 0 | 6,603,336 | 60.8% | 10 Feb, 2026 |
| 2 | Vered Bisker-Leib | Chief Executive Officer | 3,124,426 | 0 | 3,124,426 | 28.7% | 09 Feb, 2024 |
| 3 | Barry Shin | Cfo | 525,000 | 0 | 525,000 | 4.8% | 05 Jan, 2026 |
| 4 | Neil Lerner | Chief Accounting Officer | 420,000 | 0 | 420,000 | 3.9% | 02 Oct, 2026 |
| 5 | Jonathan Anderman | General Counsel | 196,000 | 0 | 196,000 | 1.8% | 30 Apr, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 01 Oct, 2026 | Neil Lerner | Chief Accounting Officer | Acquired P | 20,000 | $0.92 | $18.40K | 420,000 | Direct |
| 24 Sep, 2026 | Neil Lerner | Chief Accounting Officer | Acquired P | 2,500 | $1.14 | $2.85K | 400,000 | Direct |
| 29 Apr, 2026 | Neil Lerner | Chief Accounting Officer | Acquired P | 15,000 | $1.89 | $28.35K | 397,500 | Direct |
| 29 Apr, 2026 | Jonathan Anderman | General Counsel | Acquired P | 25,000 | $1.89 | $47.25K | 196,000 | Direct |
| 29 Apr, 2026 | Jonathan Anderman | General Counsel | Acquired A | 25,000 | $1.89 | $47.25K | 196,000 | Direct |
| 29 Apr, 2026 | Neil Lerner | Chief Accounting Officer | Acquired A | 15,000 | $1.89 | $28.35K | 397,500 | Direct |
| 08 Feb, 2026 | Thomas J. Schuetz | Chief Executive Officer | Disposed F | 36,687 | $6.52 | $239.20K | 6,603,336 | Direct |
| 09 Jan, 2026 | Thomas J. Schuetz | Chief Executive Officer | Disposed F | 46,777 | $5.35 | $250.26K | 6,640,023 | Direct |
| 02 Jan, 2026 | Ellen Chiniara | Director | Acquired A | 90,000 | $0.00 | $0 | 90,000 | Direct |
| 02 Jan, 2026 | Carl L Gordon | Director | Acquired A | 90,000 | $0.00 | $0 | 90,000 | Direct |
| 02 Jan, 2026 | James P Boylan | Director | Acquired A | 90,000 | $0.00 | $0 | 90,000 | Direct |
| 02 Jan, 2026 | Arjun Prasad | Chief Commercial Officer | Acquired A | 1,000,000 | $0.00 | $0 | 1,000,000 | Direct |
| 02 Jan, 2026 | Mary Ann Gray | Director | Acquired A | 90,000 | $0.00 | $0 | 90,000 | Direct |
| 02 Jan, 2026 | Richard S Lindahl | Director | Acquired A | 90,000 | $0.00 | $0 | 90,000 | Direct |
| 02 Jan, 2026 | Barry Shin | Cfo | Acquired A | 125,000 | $5.17 | $646.25K | 525,000 | Direct |
| 02 Jan, 2026 | Neil Lerner | Chief Accounting Officer | Acquired A | 62,500 | $5.17 | $323.13K | 382,500 | Direct |
| 02 Jan, 2026 | Thomas J. Schuetz | Ceo | Acquired A | 250,000 | $5.17 | $1.29Mn | 6,686,800 | Direct |
| 02 Jan, 2026 | Philip Ferneau | Director | Acquired A | 90,000 | $0.00 | $0 | 90,000 | Direct |
| 02 Jan, 2026 | Cynthia Sirard | Chief Medical Officer | Acquired A | 1,000,000 | $0.00 | $0 | 1,000,000 | Direct |
| 02 Jan, 2026 | Jonathan Anderman | General Counsel | Acquired A | 150,000 | $5.17 | $775.50K | 171,000 | Direct |